Here are five details:
1. The therapy is FDA approved and backed by 24-month clinical data that has proven its positive effects on patients suffering from low back and leg pain.
2. In 2016, 92 percent of HF10 Therapy’s trial patients showed more increased pain relief and subsequently decided to move forward with the permanent implant.
3. Of the patients who opted for the permanent implant, 84 percent have sustained pain relief and improvements in function. Many have also reported a decrease in their dependency on pain medications.
4. The device is considered a form of neuromodulation, which is a type of therapy that rebalances neural circuits’ activity in order to reduce pain symptoms.
5. Dr. Spiegel explains, “The device is very small and easy to implant during an outpatient surgical procedure.”
More device-related articles:
ReMAP cleared to market 7D — 5 details
Medacta acquires Vivamed: 5 key notes
FDA reclassifies pedicle screws & clarifies dynamic stabilization systems
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
